CN101478972A - 卤代芳基取代的氨基嘌呤、其组合物，和将其用于治疗的方法 - Google Patents

卤代芳基取代的氨基嘌呤、其组合物，和将其用于治疗的方法 Download PDF

Info

Publication number
CN101478972A
CN101478972A CNA2007800238554A CN200780023855A CN101478972A CN 101478972 A CN101478972 A CN 101478972A CN A2007800238554 A CNA2007800238554 A CN A2007800238554A CN 200780023855 A CN200780023855 A CN 200780023855A CN 101478972 A CN101478972 A CN 101478972A
Authority
CN
China
Prior art keywords
unsubstituted
replacement
kinase
alkyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800238554A
Other languages
English (en)
Chinese (zh)
Inventor
罗纳德·J·阿尔伯斯
莱蒂西亚·阿亚拉
史蒂文·S·克莱林
玛丽亚·默西迪丝·迪尔加多-曼德尔斯
罗伯特·希尔格拉夫
塞耶·G·赫格德
凯文·休斯
亚当·考伊斯
薇罗尼卡·普朗特维-克拉尼斯基
梅格·麦卡里克
利萨·纳多尔尼
摩尔西·S.S.·帕兰克
基兰·萨哈斯拉姆赫
约翰·塞派泽
佐藤喜孝
玛丽安·K·斯洛斯
伊莉斯·萨德贝克
乔纳森·赖特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signal Pharmaceuticals LLC
Original Assignee
Signal Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharmaceuticals LLC filed Critical Signal Pharmaceuticals LLC
Priority to CN201310180773.8A priority Critical patent/CN103351389B/zh
Publication of CN101478972A publication Critical patent/CN101478972A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2007800238554A 2006-04-26 2007-04-25 卤代芳基取代的氨基嘌呤、其组合物，和将其用于治疗的方法 Pending CN101478972A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310180773.8A CN103351389B (zh) 2006-04-26 2007-04-25 卤代芳基取代的氨基嘌呤、其组合物，和将其用于治疗的方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/411,413 2006-04-26
US11/411,413 US7521446B2 (en) 2005-01-13 2006-04-26 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201310180773.8A Division CN103351389B (zh) 2006-04-26 2007-04-25 卤代芳基取代的氨基嘌呤、其组合物，和将其用于治疗的方法

Publications (1)

Publication Number Publication Date
CN101478972A true CN101478972A (zh) 2009-07-08

Family

ID=38462340

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310180773.8A Expired - Fee Related CN103351389B (zh) 2006-04-26 2007-04-25 卤代芳基取代的氨基嘌呤、其组合物，和将其用于治疗的方法
CNA2007800238554A Pending CN101478972A (zh) 2006-04-26 2007-04-25 卤代芳基取代的氨基嘌呤、其组合物，和将其用于治疗的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201310180773.8A Expired - Fee Related CN103351389B (zh) 2006-04-26 2007-04-25 卤代芳基取代的氨基嘌呤、其组合物，和将其用于治疗的方法

Country Status (14)

Country Link
US (2) US7521446B2 (OSRAM)
EP (1) EP2010186B1 (OSRAM)
JP (1) JP2009535346A (OSRAM)
KR (1) KR20090013804A (OSRAM)
CN (2) CN103351389B (OSRAM)
AU (1) AU2007243287B2 (OSRAM)
BR (1) BRPI0710805A2 (OSRAM)
CA (1) CA2684999C (OSRAM)
ES (1) ES2400257T3 (OSRAM)
IL (1) IL194865A (OSRAM)
MX (1) MX2008013616A (OSRAM)
NZ (1) NZ572467A (OSRAM)
WO (1) WO2007127382A1 (OSRAM)
ZA (3) ZA200809356B (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105144689A (zh) * 2013-04-26 2015-12-09 富士胶片株式会社 摄像装置及图像显示方法
CN113248506A (zh) * 2014-10-06 2021-08-13 西格诺药品有限公司 取代的氨基嘌呤化合物、其组合物及其治疗方法

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7256196B1 (en) * 2003-12-09 2007-08-14 The Procter & Gamble Company Purine cytokine inhibitors
US7759342B2 (en) * 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US7521446B2 (en) * 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
NZ572381A (en) * 2006-04-28 2011-01-28 Shionogi & Co Amine derivative having npy y5 receptor antagonist activity
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
ES2567051T3 (es) * 2006-10-27 2016-04-19 Signal Pharmaceuticals, Llc Formas sólidas que comprenden 4-[9-(3S)-(tetrahidro-furan-3-il)-8-(2,4,6-trifluoro-fenilamino)-9H-purin-2-ilamino]-trans-ciclohexan-1-ol, sus composiciones y sus usos
WO2008112311A1 (en) 2007-03-14 2008-09-18 Washington University Methods for identifying diabetes and obesity therapeutics
SA08290668B1 (ar) 2007-10-25 2012-02-12 شيونوجي آند كو.، ليمتد مشتقات أمين لها نشاط مضاد لمستقبل npy y5 واستخداماتها
WO2009078999A1 (en) 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
WO2009079000A1 (en) * 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolopyrimidine modulators of trpv1
BRPI0917791B1 (pt) 2008-08-22 2022-03-22 Novartis Ag Compostos de pirrolopirimidina como inibidores de cdk, bem como composição farmacêutica e combinação
UY32138A (es) * 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
UY32470A (es) * 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
US8227618B2 (en) * 2009-04-23 2012-07-24 Shionogi & Co., Ltd. Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof
US20130034495A1 (en) * 2009-12-09 2013-02-07 Marie Georges Beauchamps Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
US9205577B2 (en) * 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
US11202853B2 (en) * 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8680076B2 (en) 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
US8674113B2 (en) 2010-12-10 2014-03-18 Boehringer Ingelheim International Gmbh Compounds
US20140213553A1 (en) 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
US9493464B2 (en) 2012-02-29 2016-11-15 The Scripps Research Institute Wee1 degradation inhibitors
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
CN109819649B (zh) 2016-04-01 2023-02-28 西格诺药品有限公司 氨基嘌呤化合物的固体形式及其使用方法
SG10202009589UA (en) 2016-04-01 2020-10-29 Signal Pharm Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
WO2017210399A1 (en) 2016-06-02 2017-12-07 Celgene Corporation Animal and human anti-malarial agents
AR108665A1 (es) 2016-06-02 2018-09-12 Celgene Corp Derivados de aminopurina como agentes anti-tripanosómicos y anti-leishmania
CN106265673B (zh) * 2016-09-18 2019-09-20 中国农业大学 一种化合物的应用
WO2019070827A1 (en) 2017-10-04 2019-04-11 Celgene Corporation PROCESSES FOR THE PREPARATION OF CIS-4 [2 - {(3S, 4R) -3-FLUOROOXAN-4-YL] AMINO) -8- (2,4,6-TRICHLOROANILINO) -9H-PURIN-9-YL] -1 -MÉTHYLCYCLOHEXANE-1-carboxamide
CA3078368A1 (en) 2017-10-04 2019-04-11 Celgene Corporation Compositions and methods of use of cis-4-[2-{[(3s,4r)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-methylcyclohexane-1-carboxamide
CN109384788B (zh) * 2018-10-16 2021-05-14 成都大学 嘌呤系列衍生物及其制备方法和用途
CN111544657B (zh) * 2020-05-11 2022-01-11 北京大学第三医院（北京大学第三临床医学院） 一种具有良好可打印性的细胞3d打印生物墨水制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332744A (en) * 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
JP2001516694A (ja) * 1997-08-07 2001-10-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア プロテインキナーゼ、ｇプロテイン及びポリメラーゼのプリン阻害剤
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
CN1919859A (zh) 1999-11-12 2007-02-28 法玛赛特有限公司 2＇－脱氧－l－核苷的合成
WO2001049688A1 (en) 2000-01-07 2001-07-12 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
AU2001295026B2 (en) 2000-09-06 2008-04-03 Novartis Vaccines And Diagnostics, Inc. Inhibitors of glycogen synthase kinase 3
PL211125B1 (pl) 2000-09-11 2012-04-30 Novartis Vaccines & Diagnostic Pochodne chinolinonu jako inhibitory kinazy tyrozynowej, kompozycje je zawierające i ich zastosowanie
EP1381594A1 (en) 2001-04-13 2004-01-21 Boehringer Ingelheim Pharmaceuticals Inc. Urea compounds useful as anti-inflammatory agents
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
US7256196B1 (en) * 2003-12-09 2007-08-14 The Procter & Gamble Company Purine cytokine inhibitors
AU2005298637B8 (en) 2004-10-29 2012-12-06 Janssen Sciences Ireland Uc HIV inhibiting bicyclic pyrimidine derivatives
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7759342B2 (en) * 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
ES2567051T3 (es) 2006-10-27 2016-04-19 Signal Pharmaceuticals, Llc Formas sólidas que comprenden 4-[9-(3S)-(tetrahidro-furan-3-il)-8-(2,4,6-trifluoro-fenilamino)-9H-purin-2-ilamino]-trans-ciclohexan-1-ol, sus composiciones y sus usos

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105144689A (zh) * 2013-04-26 2015-12-09 富士胶片株式会社 摄像装置及图像显示方法
CN105144689B (zh) * 2013-04-26 2018-04-13 富士胶片株式会社 摄像装置及图像显示方法
CN113248506A (zh) * 2014-10-06 2021-08-13 西格诺药品有限公司 取代的氨基嘌呤化合物、其组合物及其治疗方法

Also Published As

Publication number Publication date
ES2400257T3 (es) 2013-04-08
WO2007127382A1 (en) 2007-11-08
CN103351389B (zh) 2015-10-28
CA2684999A1 (en) 2007-11-08
CN103351389A (zh) 2013-10-16
BRPI0710805A2 (pt) 2011-08-16
US20070060598A1 (en) 2007-03-15
US20090275564A1 (en) 2009-11-05
IL194865A (en) 2015-08-31
AU2007243287A1 (en) 2007-11-08
MX2008013616A (es) 2009-03-06
EP2010186A1 (en) 2009-01-07
ZA201103036B (en) 2012-08-29
JP2009535346A (ja) 2009-10-01
IL194865A0 (en) 2009-08-03
ZA200907418B (en) 2011-12-28
EP2010186B1 (en) 2012-12-26
CA2684999C (en) 2013-11-26
NZ572467A (en) 2010-10-29
AU2007243287B2 (en) 2012-02-16
ZA200809356B (en) 2010-02-24
US8101588B2 (en) 2012-01-24
KR20090013804A (ko) 2009-02-05
US7521446B2 (en) 2009-04-21

Similar Documents

Publication Publication Date Title
CN101478972A (zh) 卤代芳基取代的氨基嘌呤、其组合物，和将其用于治疗的方法
EP2112151B1 (en) Haloaryl substituted aminopurines for use in treatment
US9725450B2 (en) Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
CN101142215A (zh) 卤代芳基取代的氨基嘌呤、其组合物及其治疗方法
HK1131568A (en) Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
HK1114098A (en) Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
HK1136558B (en) Haloaryl substituted aminopurines for use in treatment
HK1154581A (en) Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1131568

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20090708

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1131568

Country of ref document: HK